AstraZeneca Gains Rights to RQ Biotechnology’s COVID-19 Monoclonal Antibodies

UK-based RQ Biotechnology has secured a licensing deal with AstraZeneca (AZ), which is aiming to use the company’s portfolio of early-stage monoclonal antibodies for treatment of COVID-19.

Under the deal, which includes $157 million upfront plus potential milestone payments, AZ has acquired an exclusive worldwide license to develop, manufacture and commercialize the RQ Bio antibodies against SARS-CoV-2.

“The COVID-19 pandemic has changed the landscape for immune therapies, including the use of monoclonal antibodies to protect vulnerable patients who can’t respond adequately to vaccination alone,” said Iskra Reic, AZ’s executive vice president for vaccines and immune therapies.